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Systemic Lupus Erythematosus affects several people around the world
and because it is characterized as a chronic inflammatory disease of
multifactorial origin, and with systemic impairment, great attention
must be paid from diagnosis to treatment in order to optimize the entire
follow-up of the patient.
The dental doctor plays an important role in the diagnosis of the
condition and must be attentive to the early signs that can appear in
the oral cavity with a frequency of up to 21%.
In this way, through this bibliographic review, which has asmain goal to
correlate Systemic Lupus Erythematosus with its direct consequences
in the oral cavity, it will be possible to help dentists in the diagnosis, to
understand in detail the development of the disease and what attitude
should be taken in its presence.
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1 INTRODUCTION:
Systemic Lupus Erythematosus (SLE) is anautoimmune, multisystemic and chronic in-flammatory disease of the connective tissue,
characterized by the production of antibodies against
various cellular constituents. The disease can lead to
a wide variety of signs and symptoms, and there may
be periods of exacerbation with recurrences and re-
missions depending on the individual, the therapeutic
management, and other unknown factors (1,2).
SLE has several clinical manifestations, which may
affect one or more organs and systems. In this pathol-
ogy, the immune complex no longer recognizes the
cell antigens, which leads to a deficiency in the reg-
ulatory mechanisms and leads the antibodies to act
against the organism itself, causing hypersensitivity
reactions, injuries, inflammation and pain (3).
Despite the advances made over the years, little is
known about the etiology of the disease. This pathol-
ogy is more common in women under reproductive
age and may be associated with other autoimmune
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diseases, being its development affected by environ-
mental factors and genetic predispositions (2,3). In
the scientific world, this fact can be observed by
the greater involvement of monozygotic twins, when
compared to the dizygotic twins (2).
SLE patients are affected by a variety of orofacial
disorders. These oral manifestations are moderately
frequent, affect 9 to 45% of patients and may be the
first signs of disease or systemic changes related to
a specific treatment (1,4). The most affected areas
are the tongue, cheek mucosa, lips and palate, being
the most common acute ulcerations and/or erythema
(2), as well as angular cheilitis, mucositis, glossitis,
discoid lesions and white lines that resemble oral
lichen planus (1).
There seems to be a possible association between
periodontal disease and SLE. Periodontitis can vary
in severity regardless of the degree of bacterial infec-
tion, thus suggesting that dysregulation of the host’s
inflammatory response can be considered a trigger
for the evolution of the autoimmune disease (5).
SLE patients may also show other oral manifesta-
tions such as diseases in the salivary glands, dry
mouth, and temporomandibular disorders (4). Con-
sequently, these patients need special oral care, due
to their susceptibility to infections (2).
Thus, the goal of this studywas to conduct a literature
review focusing on the relevant aspects related to
the recognition of oral manifestations of the disease
and systemic conditions, in order to offer health
professionals a deeper knowledge on the subject.
2 MATERIALS AND METHODS:
To carry out this bibliographic review, the online
databases PubMed, Scielo and Lilacs were used, and
the keywords found to better describe the themewere
Lupus Erythematosus; Systemic Lupus Erythemato-
sus; Oral Manifestations. The selection criterion was
based on the use of considerably recent scientific
articles and the old ones were selected according to
their relevance to the subject addressed.
3 CHARACTERIZATION:
Lupus erythematosus can be divided into discoid
lupus erythematosus (DLE), limited to erythematous
patches on the patient’s skin, and systemic lupus
erythematosus (SLE), the most recurrent, that affects
several organs and systems of the body (skin, kid-
neys, heart, lungs, bloodstream and joints).
SLE is a chronic autoimmune disease of inflam-
matory origin with several clinical manifestations,
including in the oral cavity. Among the most well-
known general signs and symptoms are those that
manifest mainly in the skin (80% of the time, as
is the case of the butterfly-shaped rash), in mus-
culoskeletal tissues and at the hematological and
serological level. According to the American Col-
lege of Rheumatology (ACR), the presence of SLE
characteristics in the oral mucosa, such as ulcers,
is considered one of the criteria for diagnosing the
disease (6,7).
SLE manifests itself in different ways because it
is a multisystem disease. For this reason, diagnosis
requires special attention to be correctly determined.
According to the ACR, 11 criteria must be used
to facilitate the diagnosis of SLE. These are malar
and discoid rashes, photosensitivity, oral ulcers, non-
erosive arthritis, pleuritis or pericarditis, renal, neu-
rological, hematologic and immune impairments,
and presence of antinuclear antibodies. When 4 of
these criteria are present, there is a high probability
of being SLE (6).
According to Albilia et al. (8) some of the most com-
mon symptoms in this disease are fatigue, malaise,
arthralgia (when the inflammatory condition be-
comes known as arthritis), myalgia and mucocu-
taneous lesions. Although arthralgia is the earliest
manifestation of SLE, musculoskeletal involvement
seems to be the predominant symptom in the dis-
ease, as well as the development of generalized skin
rashes, induced by sunlight and discoid lesions sec-
ondary to epithelial atrophy with subsequent healing.
One of the most striking features of the skin rashes
observed is the shape of a butterfly symmetrically
located in themalar and back of the nose (8). A recent
study points out for the divergence of cutaneous
lupus manifestations that may present in a single
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patient over a period of time (9). This indicates the
importance of a clinical-pathological correlation for
the correct diagnostic of this condition and for the
choice of the adequate therapeutic approach.
Studies indicate that SLE has a prevalence of 30 to
50 cases per 100,000 inhabitants and its incidence
ranges from 0.9 to 3.1% per 100,000 inhabitants per
year. Women between 30 and 40 years of age are the
most affected, with a 10:1 ratio to men (8,10).
4 ETIOLOGY:
The development of the pathology is based on
an exaggerated inflammatory process with vascular
changes that involve vasculopathy and deposition
of immune complexes. These immunocomplexes are
often composed of IgG and IgM and eventually IgE
and lead to a generalized or organ-specific type III
hypersensitivity reaction (8,11).
An important immunological data that defines the
pathogenesis of SLE is the production of autoanti-
bodies that end up acting directly on one or more
proteins of the individual, characterizing what is
popularly known as an autoimmune disease. The
production of autoantibodies causes tissue damage
promoted by an inflammatory response mediated by
the previously mentioned immunocomplexes (12).
There is strong evidence that the development of
SLE has genetic influences such as polymorphic
genes, however, there are also factors of environ-
mental origin that can influence the predisposition
of individuals to the appearance of this condition.
Among these factors are infections (mainly by the
Epstein-Barr virus), excessive sun exposure and the
use of certain medications such as hydralazine, pro-
cainamide, phenytoin, and isoniazid (8).
3.1. Genetic factors
Although the etiopathogenesis of SLE is still un-
known, research indicates that genetic, hormonal,
and environmental factors are related to the devel-
opment of immunological abnormalities that charac-
terize this disease (13).
The evidence of genetic susceptibility associated
with the development of SLE is the 10-fold increase
in the occurrence of the disease inmonozygotic twins
when compared to dizygotic twins, in addition to the
presence of autoantibodies and cellular changes in
the relatives of patients (13-16).
Studies suggest that the most common genetic
changes associated with SLE are those found at
the main histocompatibility complex locus (MHC
or HLA). The predisposing loci are HLA-DR2 and
HLA-DR3 and these gene regions encompass several
genes whose interactions are complex and vary in
different ethnic groups. Thus, the HLA-DRB1, HLA-
DRB1*0301 and HLA-DRB1*1501 loci have been
associated with the development of SLE, whileHLA-
DRB1*1401 reduces the risk of this disease (13,17).
Factors of genetic vulnerability to the development
of SLE are the combination of the presence of sus-
ceptibility genes with the absence of protective genes
such as the TLR5 polymorphisms or the genetic vari-
ant with loss of function of the tyrosine phosphatase
protein, non-receptor, type 22 (PTPN22 ) (13).
A recent study identified a novel susceptibility gene
to SLE (18). These researchers were able to conclude
that the allele rs2582511 of the gene PLD4, coding
for phospholipase D4 is associated with anti-dsDNA
antibody production, leading to autoimmune pheno-
types compatible with SLE, including splenomegaly
and lymphadenopathy (18).
3.2. Environmental factors
Some environmental factors may be related to the
development of SLE. One of the most discussed in
the literature is the influence of the Epstein-Barr
virus (EBV) on the development of the condition.
This is due not only to the fact that high proportions
of anti-EBV antibodies have been found in patients
with SLE, but also to the finding that EBV infection
precedes the autoimmune changes seen in SLE (2).
In addition to EBV, SLE can be induced by some
drugs, with procainamide being responsible for most
cases. When the drug influence is confirmed in the
diagnosis, it is possible to verify the presence of anti-
histone antibodies. In clinical terms, some throm-
boembolic consequences can also be observed. In
these cases, the great advantage is the possibility of
the disappearance of the condition by interrupting the
JMCRR 3 (9), 444−453 (2020) MANUSCRIPT CENTRAL 446
MANUSCRIPT CENTRAL
CARDOSO, LEAL AND REGIS
use of the medication (19).
Vitamin D deficiency, exposure to silica and tobacco
consumption have also been identified as environ-
mental factors involved in the development of SLE,
since they reduce tolerance to autoantigens. In the
case of vitamin D, patients with SLE show extremely
low levels of this vitamin. The influence of silica,
present mainly in materials used in restoration work,
has been confirmed in several case-control studies
with patients exposed to this substance. Finally, to-
bacco also seems to influence the development of
this disease, especially during the appearance of skin
lesions (20,21).
Other factors such as exposure to metals, pesticides
and pollutants and even cosmetics may be related to
SLE, however, despite the evidence of their asso-
ciation with SLE, further studies are necessary due
to the divergence of results presented in different
researches (21).
5 ORAL MANIFESTATIONS:
Systemic autoimmune diseases often present oral
changes in their early stages of development. SLE is
included in this group, which facilitates early diagno-
sis and intervention. Oral manifestations appear with
a frequency of 6.5 to 21% of SLE cases, being the
most affected regions the cheekmucosa, tongue, lips,
and palate. The lower lip region may show fissures,
bleeding and edema (22).
Although some cases of this pathology do not present
a precise symptomology, in cases with oral lesions,
it is mainly observed well-defined chronic ulcerated
areas or with an erythematous aspect. These areas
vary in size and are characterized by having the
center in the form of whitish papules surrounded by
streaks also of white color. Its appearance involves
periods of remission and crises (7,10).
5.1. Gingivitis and periodontal disease
One of the implications of SLE is the development
of gingival inflammation (gingivitis) and periodontal
disease that directly affect the support and support
structures of the teeth. The most common types of
gingivitis are scaly gingivitis andmarginal gingivitis,
which have a strong relationship with the accumula-
tion of plaque that is retained by the gingival tissue.
This plaque results from the poor oral hygiene of
patients with SLE, associated with discomfort in the
oral cavity, which ends up discouraging or hindering
their hygiene, resulting in the formation of dental
calculus plates (8).
In turn, periodontal disease, despite having a differ-
ent etiology fromSLE, seems to have some similarity
with autoimmune disease regarding the mechanism
of action. Both occur due to dysregulation of the
affected individual’s innate immune system, with in-
volvement of cytokine gene polymorphisms such as
interleukin 10 (IL-10), tumor necrosis factor (TNF)
and IgG Fc receptor in both conditions (2).
Calderaro et al. (23) evaluated the severity of the
periodontal condition in patients with and without
SLE, in samples of the same gender, age, socioeco-
nomic and cultural level, suggesting that there is no
difference in the periodontal condition. According
to these authors, in patients with SLE, periodontal
disease manifested earlier than in healthy controls,
suggesting the need for strict periodontal monitoring
of patients with this pathology.
Umbelino Junior et al. (2) suggested that SLE pa-
tients need more care with oral diseases. It was ob-
served an index of periodontal pockets and bleeding
18% higher than the general population and it has
also been reported that the presence of SLE can
influence the progression of these diseases due to its
inflammatory character and its susceptibility to in-
fectious agents. It is emphasized that further studies
are needed to prove this assumption.
However, Mutlu et al. (24) observed that SLE pa-
tients had smaller periodontal pockets when com-
pared to the control group. These authors suggested
that these observations may be related to the possi-
bility that the patients examined are under prolonged
therapy with immunosuppressants, corticosteroids
and non-steroidal anti-inflammatory drugs.
Still other studies have shown that patients with
SLE had plaque indices like individuals without this
condition (23). In another study, greater depth of
periodontal pockets was observed in individuals with
SLE when compared to healthy individuals (24).
MANUSCRIPT CENTRAL JMCRR 3 (9), 444−453 (2020) 447
SYSTEMIC LUPUS ERYTHEMATOSUS AND IMPLICATIONS FOR THE ORAL CAVITY
It is important to note that SLE, being an inflam-
matory disease, can aggravate patients’ periodontal
conditions and consequently contribute to greater
tooth loss (5,25).
As can be concluded from the studies presented,
there are controversies regarding the possible asso-
ciation between SLE and periodontal disease. How-
ever, it is recommended that patients with this au-
toimmune disease undergo periodic follow-up (23).
5.2. Hyposalivation and xerostomia
The sensation of decreased amount of saliva (xeros-
tomia) and hyposalivation are conditions that occur
frequently in cases of SLE, as a result of the use
of certain medications such as non-steroidal anti-
inflammatory drugs, corticosteroids and immuno-
suppressants that can considerably affect the amount
and quality of saliva produced (11,26).
This dysfunction of the salivary glands can also
occur due to chronic inflammation resulting from
autoimmune disease. Studies demonstrate an associ-
ation of SLE with another autoimmune disease, Sjö-
gren’s syndrome, which affects the salivary glands
and generates glandular involvement in a similar way
to what occurs in SLE (11,26).
Gilboe et al. (27) found a prevalence of xerostomia
in 37% of SLE cases. This symptomology was more
common in these patients when compared to healthy
people or patients with rheumatoid arthritis.
As a result of the reduction in saliva production,
patients are predisposed to the development of dental
caries, periodontal disease, non-infectious pharyngi-
tis and to the appearance of ulcers. In addition, it is
possible to verify the onset of mucositis that com-
promises the ingestion and swallowing of food and
promotes a reduction in the quality of oral hygiene
(8).
The salivary decrease that leads to low lubrication,
also compromises daily activities such as eating,
which can lead to dysphagia (difficulty in swallow-
ing) and dysgeusia (taste change) (28).
5.3. Temporomandibular joint disorders
Arthritis and arthralgia (joint pain) are common in
patients with SLE, and the involvement of the tem-
poromandibular joint (TMJ) may also be present,
reported in 60% of cases (6).
TMJ disorders are a consequence of ligament laxity,
increased contractures, and muscle atrophy. The lit-
erature states that patients undergoing immunosup-
pressive therapy for the treatment of SLE are most
affected by TMJ disorders in their different degrees
of severity, which may include limited mouth open-
ing and changes in laterality (1,6,26).
TMJ dysfunctions have been reported in 41% of
SLE patients, being proven by radiographic changes
in 30% of cases. Among these changes, the most
observedwere flattening and erosion of themandibu-
lar condyle. Studies have suggested an association
between TMJ deformations and other joints (4,29).
5.4. Ulcers and recurrent aphthous stomatitis
Mainly located in the gingiva, oral mucosa, redness
of the mouth and palate, ulcers together with the
burning sensation are characteristics of high inci-
dence in patients with SLE, varying between 7 and
41% according to recent literature (10). These lesions
can start as petechiae and evolve into ulcerated le-
sions that can present painful symptoms (10,11,30).
The ulcers commonly present in SLE, when they
become chronic, pose a risk of malignant transfor-
mation to squamous cell carcinoma. Therefore, it is
recommended to perform biopsies and repeat them
when the diagnosis is uncertain or the lesions appear
to have no improvement, so that the treatment is
carried out as soon as possible (7,22).
Recurrent aphthous stomatitis (RAS) is also a com-
mon sign of SLE and can be seen in the early stages
of the disease, thus being a sign of great relevance for
early diagnosis. It should be noted that pediatric pa-
tients with DLE and mucosal involvement, including
RAS lesions, are more likely to make the transition
to SLE (22).
6 DIAGNOSIS:
The diagnosis of SLE is clinical, anatomopatholog-
ical and serological. When symptoms already exist,
the diagnosis becomes essential, since the prognosis
depends on the early treatment of the disease (19).
The markers of this disease are the anti-nucleosome
antibodies (autoantibody against the chromatin con-
stituent nucleosomes), anti-native DNA (antibody
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characteristic of SLE patients), anti-Sm (autoanti-
body specific to SLE) and anti-Ro (antibody against
the Ro antigen which can be found in SLE, Sjogren’s
Syndrome or Rheumatoid Arthritis) (31).
The diagnostic importance is in the presence of
DNAn as an antigen (called native or double helix
DNA) that leads to the production of an anti-DNA
autoantibody, present in 70% to 80% of patients
with the disease. Anti-DNAn antibodies are found
almost exclusively in SLE patients and are therefore
considered to be markers of this disease. The most
used tests for its detection are those of indirect im-
munofluorescence, which have less sensitivity, but
great specificity for SLE, and ELISA that allows
the detection of less specific antibodies and greater
sensitivity at the expense of specificity (32).
For the correct diagnosis to be made, a detailed
intraoral clinical examination is of great importance.
Care when assessing the oral cavity allows for better
planning for choosing an appropriate treatment, with
consequent risk reduction and favorable prognosis.
However, despite the relevance of this stage, many
dentists end up not prioritizing it and the results can
lead to a compromised patient’s health (26).
Although the oral manifestations of SLE have quite
striking characteristics, there are some other con-
ditions that can be confused with this pathology.
The differential diagnosis includes lichen planus,
erythemamultiforme, traumatic lesions, leukoplakia,
candidiasis, lichenoid reactions to metal restorations
(amalgam) or drugs (beta-blockers or non-steroidal
anti-inflammatory drugs) and other vesicle-bullous
lesions (7,8).
In addition to the importance of correct diagnosis,
it is necessary to warn that studies have shown an
increase in squamous cell carcinoma in chronic ul-
cerous lesions in patients with SLE, which reaffirms
the need for a detailed intraoral examination (7,8).
In the diagnosis of a recurrent aphthous ulceration
(RAU), it is important to assess the association of
the oral manifestation with a systemic disease. This
diagnosis must be made through a detailed anam-
nesis and blood tests such as complete blood count
and assessment of vitamin B12, iron and folate de-
ficiency. If the dentist is unsure of the diagnosis, a
biopsy may be necessary. Some authors claim that
with the definitive diagnosis of RAUwithout painful
symptoms, treatment is not necessary (33-35).
7 TREATMENT:
According to the American Academy of Dermatol-
ogy, the main recommendations for the treatment
of SLE with mucocutaneous manifestations are to
avoid sun exposure and if you do so, wear protec-
tive clothing or photoprotectors with minimal UVB-
15 protection; use of topic corticosteroids; systemic
therapies that include first-line antimalarial drugs,
aminoquinoline, dapsone and prednisolone (12).
The treatment of lupus erythematosus, in its two
forms (discoid and systemic), begins with general
measures such as counseling, support and guidance
for patients and their families, as well as multidis-
ciplinary treatment. In addition, treatment should
be supplemented with dietary guidance for the pre-
vention and control of osteoporosis, obesity, and
systemic arterial hypertension. Protective measures
against sunlight and other forms of ultraviolet radi-
ation are required using topical photoprotectors and
physical barriers such as long-sleeved clothing and
the use of a hat.
The use of medications for the treatment of SLE
may explain the lack of conclusive results in attempts
to correlate oral and skin manifestations with the
prognosis of the disease (36), as these alter the mu-
cosa, making it difficult to determine the etiology
of oral lesions in these individuals (37,38). Scully
(34) created an organization chart that facilitates
the follow-up of the treatment of SLE, which must
be done in a multidisciplinary way and associated
with some medications depending on the systemic
involvement of the disease.
Patients with SLE and the presence of mouth ulcers
and gingivitis are treated effectively with topic cor-
ticosteroid medications. However, according to re-
search, the continuous contact of the medication with
the lesion surface in the oral mucosa is more difficult
to be achieved, being, in these cases, necessary to
prescribe aerosol medications. It is also useful to use
antimalarials to control oral lesions (29,37). Some
authors have observed fungal infections in SLE pa-
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tients, mainly during immunosuppressive therapy
and/or during the exacerbation of the disease (39).
SLE patients should be instructed to use soft tooth-
brushes and fluoride products due to the potential to
reduce acidity, dental caries, and possible infections.
In addition, it is important to warn patients of the
extreme importance of avoiding foods with spices
and/or peppers, as well as acidic fruits, as they can
aggravate ulcers and other lesions present and gen-
erate even more discomfort (26).
Some authors consider it necessary to perform
panoramic X-rays of the TMJ, as a form of control,
to assess possible bone changes in this structure
(11,40).
8 DISCUSSION:
Lupus erythematosus is an autoimmune disease char-
acterized by chronic inflammation, the etiology of
which is still poorly understood. SLE is an au-
toimmune, chronic inflammatory, multisystemic and
complex disease. This pathology evolves with poly-
morphic clinical manifestations, with periods of ex-
acerbation and remission. According to several stud-
ies, environmental factors, genetic predispositions,
and the use of some medications are related to the
development of this disease (1,41).
The correct diagnosis and control of autoimmune
disease requires a multidisciplinary medical team,
including the dentist (22,42). SLE patients are af-
fected by a variety of oral changes. The literature
is still scarce on this subject and it is difficult to
make it evident that there is any association between
systemic disease and oral alterations. The manifes-
tations present in the oral cavity vary according to
the severity of the disease. According to Mustafa
et al. (43), oral lesions, when present, are usually
multiple and distributed asymmetrically, and may be
asymptomatic in 50% of patients.
The literature presents a lower frequency of reports
on oral lesions in patients with SLE, compared to
reports describing skin lesions. This fact can be
explained by the lack of incidence of ultraviolet radi-
ation in the oral cavity in contrast to the skin (36). Ac-
cording to Louis & Fernandes (19), the oral regions
most affected by SLE are those of the vestibular
mucosa, gums and lips due to the susceptibility to the
development of cheilitis, although lupus can affect
any surface of the oral mucosa.
The lesions can manifest as erosion in the mucosa,
ulcers surrounded by an irradiated striated pattern,
flaking surface plaques and fissures with hemor-
rhagic tendency, incidence of ulcerations, erythema
and keratosis, present on the tongue, cheek mucosa,
gums and hard palate, resulting from tissue damage
caused by immune complex-mediated vasculopathy.
In addition, several studies report the risk of possible
malignancy of some oral ulcers (2,8,44,45).
Regarding the age group, SLE has a predilection for
women of childbearing age in the second and third
decades of life and may be associated with other
autoimmune diseases (2,3,10,31). It can also affect
other ages, both sexes, with all races being affected,
although the disease is more severe in the black race
(46-48).
In the study by Umbelino Junior et al. (2), in which
the incidence of oral manifestations in SLE was
assessed, a prevalence of oral lesions of 6.5% was
observed, hairy leukoplakia in 3.7% and candidiasis
in 20.0% of SLE cases. Although there is a fre-
quency of oral lesions in SLE, overall, the specific
prevalence of oral manifestations in females is low
(47,49).
There are few reports in the literature associating
SLE with periodontal disease. Studies have shown a
potential association between these two pathologies,
indicating that dysregulation of the host’s inflamma-
tory response has an influence on disease progression
(5,50,51).
Several studies claim that the involvement of sali-
vary glands in SLE is associated with the presence of
secondary Sjögren’s syndrome (8,52,53). However,
other studies report patients with xerostomia without
an association between the two pathologies (27,54).
The therapeutic choice for SLE is individualized and
depends on the symptomatic manifestations and the
severity of the disease. However, it is a consensus
that all patients with SLE should start treatment with
drug therapy unless there is an evident contraindica-
tion (55).
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Due to the variability of orofacial disorders that
affect patients with SLE including oral lesions, non-
specific ulcerations, involvement of salivary glands
and TMJ problems, it is important that the dentist
is attentive to the signs and symptoms of the oral
condition that can serve for the diagnosis early SLE.
9 CONCLUSION:
Despite the innumerable advances in knowledge
about the functioning of the immune system in nor-
mal and pathological conditions, more studies are
needed to be able to act in its prevention, or at least
in an earlier diagnosis.
Since SLE affects the oral cavity, it is important
that the dentist knows how to assess, diagnose, and
treat oral changes, aiming at a local and systemic
improvement. The dentist, in agreement with amulti-
disciplinary team, must be aware of drug interactions
and surgical interventions to improve oral health to
avoid systemic complications. In this way, it will
be possible to develop more effective therapies with
less adverse effects that enable the remission of the
disease and provide quality of life to patients.
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